IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
Life review of elderly depression
Development and application of ATR-FTIR spectroscopy for mixture homogeneity in pharmaceutical application
The Increasing Damage in Tubular Cell of Infant Mice’s Kidneys from Carbofuran Exposure during its Mothers’ Lactation Period
Trend of transsexualism problem and its implications towards muslim community in Malaysia
Development and validation of RP-HPLC method for the estimation of pidotimod in tablet dosage form
Evaluation of neurotoxicity of the ethanolic bark extract of Holarrhena pubescens Wall. ex G.Don in mice
Design, synthesis and evaluation of 2-aminobenzimidazole derivatives: strong candidate for PPAR gamma agonists.
Prediction of Heart Disease Using Feature Selection and Random Forest Ensemble Method
Strategies for Antiviral Drugs from Plants by Targeting the Hemagglutinin, Neuraminidase and other receptors of Influenza A virus
The impact of human resource and quality management in health care: A Review
12345678910...
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Formulation and Evaluation of Delayed Release Capsule of Dimethyl Fumarate with Novel Technology

Author: ANJALI KUMARI, RAJESH KUMAR, BALWAN SINGH
Abstract: Dimethyl fumarate is an anti-inflammatory agent which is indicated for the treatment of multiple sclerosiswith relapsing formsand for psoriasis. The aim of this study was to prepare and evaluate delayed release capsule of Dimethyl fumarate with raft technology to reduce the flushing, a common side effect. The core mini tablets were prepared by direct compression method &enteric coating was done by perforated coating pan. Preformulation studies like angle of repose, bulk density, tapped density, Carr's index,Hausner's ratio & angle of repose were carried out. Evaluation of Post compression parameters such as Hardness, thickness, friability, weight variation disintegration and dissolution. The F05 batch shows the highest drug release at 45 min in pH 6.8 phosphate buffer was 97.13 % which are the satisfactorily results. After that encapsulation done which contains enteric coated mini tablets along with raft blend sothe formulation was formed a complex gel like structure in which mini tablets are trapped and dropped one by one with specified time interval. The F05 was the optimized batch among all six batches & blend 01 among all five blends are selected as per result. The raft technology was successfully applied on delayed release capsule increaseslag time thus decreasing flushing. Stability studies indicated that the developed dosage form was stable and retained their pharmaceutical properties at room temperature and accelerated conditions.
Keyword: Dimethyl fumarate, Raft technology, Delayed release capsules, Relapsing Remitting multiple sclerosis.
DOI: https://doi.org/10.31838/ijpr/2019.11.04.073
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free